GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Wakamoto Pharmaceutical Co Ltd (TSE:4512) » Definitions » Net Cash per Share

Wakamoto Pharmaceutical Co (TSE:4512) Net Cash per Share : 円8.87 (As of Sep. 2024)


View and export this data going back to 1949. Start your Free Trial

What is Wakamoto Pharmaceutical Co Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Wakamoto Pharmaceutical Co's Net Cash per Share for the quarter that ended in Sep. 2024 was 円8.87.

The historical rank and industry rank for Wakamoto Pharmaceutical Co's Net Cash per Share or its related term are showing as below:

TSE:4512' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 11.63   Med: 42.4   Max: 1014.29
Current: 36.64

During the past 13 years, the highest Price-to-Net-Cash Ratio of Wakamoto Pharmaceutical Co was 1014.29. The lowest was 11.63. And the median was 42.40.

TSE:4512's Price-to-Net-Cash is ranked worse than
86.04% of 265 companies
in the Drug Manufacturers industry
Industry Median: 8.4 vs TSE:4512: 36.64

Wakamoto Pharmaceutical Co Net Cash per Share Historical Data

The historical data trend for Wakamoto Pharmaceutical Co's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wakamoto Pharmaceutical Co Net Cash per Share Chart

Wakamoto Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -33.21 -9.89 -6.94 2.14 7.77

Wakamoto Pharmaceutical Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Sep24
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.60 5.26 0.21 7.77 8.87

Competitive Comparison of Wakamoto Pharmaceutical Co's Net Cash per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Wakamoto Pharmaceutical Co's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wakamoto Pharmaceutical Co's Price-to-Net-Cash Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Wakamoto Pharmaceutical Co's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Wakamoto Pharmaceutical Co's Price-to-Net-Cash falls into.


;
;

Wakamoto Pharmaceutical Co Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Wakamoto Pharmaceutical Co's Net Cash per Share for the fiscal year that ended in Mar. 2024 is calculated as

Net Cash per Share (A: Mar. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(3664.647-3394.982-0)/34.707
=7.77

Wakamoto Pharmaceutical Co's Net Cash per Share for the quarter that ended in Sep. 2024 is calculated as

Net Cash per Share (Q: Sep. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(3618.168-3310.23-0)/34.707
=8.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Wakamoto Pharmaceutical Co  (TSE:4512) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Wakamoto Pharmaceutical Co Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Wakamoto Pharmaceutical Co's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Wakamoto Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
2-2-2, Nihonbashi Honcho, Chuo-ku, Tokyo, JPN, 103-8330
Wakamoto Pharmaceutical Co Ltd is the pharmaceutical company based in Japan. It is engaged in the research and development, production and sale of ethical drugs and non-prescription drugs. The company specializes in therapeutic and diagnostic agents for ophthalmic disorders. It offers Strong Wakamoto, a gastrointestinal drug for digestion, the intestinal function controlling, and nutritional supply.

Wakamoto Pharmaceutical Co Headlines

No Headlines